BCI Breakthrough: "Beinao No. 1" Advances to GCP Clinical Trials
If intention could be translated into action, could those whose minds remain imprisoned within damaged bodies once again embrace the possibilities of life?
On March 31, the "Beinao No. 1" Intelligent Brain-Computer Interface (BCI) System, jointly developed by the Chinese Institute for Brain Research, Beijing (CIBR) and Beijing CiNi Technology Co., Ltd., successfully completed implantations in the first two patients with spinal cord injury (SCI) as part of a Good Clinical Practice (GCP)-compliant multi-center clinical trial, conducted at Capital Medical University's Tiantan Hospital and Xuanwu Hospital, respectively. This milestone marks a pivotal transition for China's indigenous BCI technology — from early-stage exploration to standardized, large-scale confirmatory clinical investigation.
Restoring Hope: Building a New Pathway for Life
Spinal cord injury frequently results in the loss of fundamental motor functions such as grasping, profoundly compromising patients' quality of life. For these individuals, even the simple act of reaching out becomes an unattainable aspiration. The development of "Beinao No. 1" is precisely aimed at reconstructing this vital neural pathway.
On March 31, clinical teams at Tiantan Hospital and Xuanwu Hospital respectively performed successful implantation procedures on two patients with motor dysfunction secondary to spinal cord injury. Both patients are currently reported to be in stable postoperative condition. In accordance with the study protocol, the patients will next proceed to the BCI training and functional rehabilitation phase, with the prospect of progressively regaining partial motor function.
Over the past year, the "Beinao No. 1" system has been deployed in exploratory applications involving seven patients, accumulating a total of over 45,000 hours of safe operational runtime and providing preliminary evidence of system safety and feasibility. Building upon this foundation, the current GCP multi-center clinical trial has an initial planned enrollment of 36 patients. Through a rigorously standardized research design and long-term follow-up assessment, the trial aims to systematically evaluate the safety and efficacy of the system in restoring motor function in SCI patients, thereby generating critical evidence-based data to support subsequent clinical application and industrial translation.
The Power of CIBR: A Self-Developed "Closed-Loop" Technological System
"Beinao No. 1" not only carries the hope of patient recovery but also exemplifies China's systemic innovation capacity in the field of brain-computer interfaces. The system was independently developed by a Chinese research team led by CIBR, achieving a comprehensive technological breakthrough that encompasses all critical components — including flexible electrode arrays, signal processing, neural decoding algorithms, and external device control. It enables precise interpretation of motor intention from the brain and directly drives external devices to execute corresponding actions, thereby establishing a complete closed-loop pipeline from "neural signal → decoding → execution."
Distinct from conventional rehabilitation approaches, this system endeavors to bypass the constraints of damaged neural pathways by "reading the brain and reconstructing the pathway," offering paralyzed patients an entirely novel route to functional restoration. The flexible electrode design ensures high signal-to-noise ratio (SNR) acquisition while effectively mitigating post-implantation immune responses and tissue damage risks, providing a critical safeguard for long-term stable application.
Looking Ahead
The successful completion of the first implantations in this multi-center clinical trial represents a significant milestone for CIBR in advancing the clinical translation of brain-computer interface technology. As research continues to progress, this indigenously developed BCI technological framework holds the promise of delivering tangible and accessible rehabilitation pathways for a broader population of patients with motor dysfunction — transforming the aspiration of "moving by intention" from scientific exploration into clinical reality.
